Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimetoran (BMS-986256) PK Interaction with Loestrin
NCT04016753Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of afimetoran in systemic lupus erythematosus (SLE), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma Concentration (Cmax) of Norethindrone (NET), Area under the plasma concentration-time curve over the dosing interval AUC(TAU) of NET and 2 more. Started Aug 2019; status: completed.
02
Drugs
afimetoran
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04016753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04016753.